Stone Ridge Asset Management LLC grew its holdings in Luminex Co. (NASDAQ:LMNX) by 9.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,385 shares of the medical instruments supplier’s stock after acquiring an additional 2,027 shares during the period. Stone Ridge Asset Management LLC owned 0.05% of Luminex worth $739,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LMNX. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Luminex in the 2nd quarter worth $207,000. Crossmark Global Holdings Inc. purchased a new position in shares of Luminex in the 2nd quarter worth $214,000. Cubist Systematic Strategies LLC grew its stake in shares of Luminex by 7,572.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 7,289 shares of the medical instruments supplier’s stock worth $215,000 after buying an additional 7,194 shares in the last quarter. OppenheimerFunds Inc. purchased a new position in shares of Luminex in the 2nd quarter worth $231,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Luminex by 1,278.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 8,076 shares of the medical instruments supplier’s stock worth $238,000 after purchasing an additional 7,490 shares during the period. Institutional investors and hedge funds own 81.97% of the company’s stock.

NASDAQ:LMNX opened at $27.01 on Monday. Luminex Co. has a one year low of $18.62 and a one year high of $35.37. The stock has a market capitalization of $1.20 billion, a PE ratio of 29.68, a price-to-earnings-growth ratio of 3.13 and a beta of 0.34.

Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, November 5th. The medical instruments supplier reported $0.05 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.03). Luminex had a net margin of 5.65% and a return on equity of 5.99%. The business had revenue of $72.40 million during the quarter, compared to the consensus estimate of $74.05 million. During the same quarter in the prior year, the firm posted $0.13 EPS. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, sell-side analysts expect that Luminex Co. will post 0.58 earnings per share for the current year.

A number of equities analysts recently commented on LMNX shares. Zacks Investment Research cut shares of Luminex from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. ValuEngine cut shares of Luminex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 8th. Citigroup lifted their price target on shares of Luminex from $23.00 to $34.00 and gave the stock a “$33.58” rating in a research note on Monday, July 23rd. BidaskClub cut shares of Luminex from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 22nd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $27.00 price target on shares of Luminex in a research note on Tuesday, August 7th. Five equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $28.40.

COPYRIGHT VIOLATION WARNING: “Stone Ridge Asset Management LLC Acquires 2,027 Shares of Luminex Co. (LMNX)” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/11/19/stone-ridge-asset-management-llc-acquires-2027-shares-of-luminex-co-lmnx.html.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Featured Article: Stop Order

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.